Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma

Abstract The prognostic value of interim 18fluorodeoxyglucose positron emission tomography (i-PET) was investigated in 73 patients (median age 60 years) with diffuse large B-cell lymphoma (DLBCL). i-PET was analyzed using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Patients with a DS of 1–3 demonstrated a significantly (p < 0.0001) better outcome (median follow-up 2.4 years) than patients with a score of 4 or 5 in terms of event-free survival (EFS) (79% vs. 36%), progression-free survival (PFS) (84% vs. 47%) and overall survival (OS) (91% vs. 51%). EFS (73% vs. 42%), PFS (78% vs. 50%) and OS (88% vs. 56%) were also significantly (p = 0.023) different between patients with ΔSUVmax > 66% or ≤ 66%. Patients (n = 33) combining a favorable age-adjusted International Prognostic Index (IPI) (0 or 1) and a negative i-PET either by DS or ΔSUVmax criteria showed a particularly good outcome (EFS: 85%, PFS: 88%, OS: 94%). Overall, i-PET was highly and independently predictive of any outcome, and its negative predictive value was improved by combination with IPI.

[1]  F. De Keyzer,et al.  Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[2]  C. Moskowitz Interim PET-CT in the management of diffuse large B-cell lymphoma. , 2012, Hematology. American Society of Hematology. Education Program.

[3]  B. Coiffier,et al.  Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma , 2012 .

[4]  S. Ferrero,et al.  Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.

[5]  C. Copie-Bergman,et al.  Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.

[7]  Sang-We Kim,et al.  Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP , 2011, Annals of Hematology.

[8]  J. Min,et al.  Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. , 2011, European journal of cancer.

[9]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[10]  C. Haioun,et al.  Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010 , 2010, Leukemia & lymphoma.

[11]  M. Juweid,et al.  Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background , 2010, The Journal of Nuclear Medicine.

[12]  M. Juweid,et al.  Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[14]  K. Jöckel,et al.  Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Trotman,et al.  Role of early PET in the management of diffuse large B-cell lymphoma , 2010, Current opinion in oncology.

[16]  W. Wilson,et al.  The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma , 2010, Leukemia & lymphoma.

[17]  M. Meignan Interim PET in lymphoma: a step towards standardization , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  A. Zelenetz,et al.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Zelenetz,et al.  An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  R. Advani,et al.  Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. , 2010, Blood.

[21]  T. Terasawa,et al.  Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes , 2009, Leukemia & lymphoma.

[22]  A. Rahmouni,et al.  Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.

[23]  S. Goodman,et al.  Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[25]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[26]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[29]  A. Stamatoullas,et al.  Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[33]  I. Lossos,et al.  High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. D. van der Walt,et al.  The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. , 2005, Haematologica.

[35]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[36]  Wi Wei,et al.  Prognostic factors , 1998, British Journal of Cancer.